Business Wire

New Mobile RPG KonoSuba: Fantastic Days Passes 1 Million Downloads

Share

Today, Nexon announced that its newest free-to-play mobile RPG KonoSuba: Fantastic Days has reached a whopping one million downloads in just 5 days. Based on the hit comedy anime series streaming on Crunchyroll and HBO Max, the character-collector game is available now on iOS and Android.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005263/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

KonoSuba: Fantastic Days - 1 Million Downloads (Graphic: Business Wire)

Since its initial release and massive success in Japan in February 2020, the worldwide release on August 19, 2021 has already reached the prestigious milestone of one million downloads, with user numbers growing by the day. Players have been enjoying the chance to adventure into the fantasy world of KonoSuba, and positive response from fans has been a big factor in its rapid success.

To celebrate one million downloads, Nexon will be rewarding all players who log into KonoSuba: Fantastic Days with the following free currency gift and limited time event:

  • Reward: 1,500 Free Quartz for players who log in from 5:00 pm PDT August 30 to 8:00 am PDT September 5 (Redeemable once per account)
  • Event: Main Quest (Normal) 2x Item Drop from 1:00 am PDT August 31 to 12:59 am PDT September 3

KonoSuba: Fantastic Days features fan-favorite characters, including Kazuma Satou, Aqua, Megumin and Darkness. The characters are voiced by their original Japanese voice actors, including Jun Fukushima, Sora Amamiya, Rie Takahashi and Ai Kayano. Following an original storyline, bespoke new characters have also been created exclusively for the mobile RPG. Published by Nexon in partnership with KonoSuba publisher Kadokawa, and developed by Sumzap, KonoSuba: Fantastic Days is available now on iOS and Android.

Stay up to date about new characters, events by following KonoSuba: Fantastic Days’ Twitter @playkonosuba and by visiting the official website!

Assets: Press Assets

Social Media: Twitch / Twitter / Instagram / Discord / Facebook

About KonoSuba: Fantastic Days konosuba.nexon.com

Based on the popular anime series “KonoSuba: God's Blessing on this Wonderful World!”, KonoSuba: Fantastic Days is a free-to-play character-collection RPG for iOS and Android. Featuring fan-favorite characters, including Kazuma Satou, Aqua, Megumin and Darkness, the game follows the storyline from the original novel and includes bespoke characters created exclusively for the game. Last year, the Japanese release of KonoSuba: Fantastic Days saw great success, garnering recognition from players and praise from the KonoSuba fan base.

About Nexon America Inc. https://www.nexon.com/

Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nexon America
Brian Klotz.
pr@nexon.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CORRECTING and REPLACING PHOTO Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 21:23:00 EEST | Press release

Please replace the photo with the accompanying corrected photo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. The release reads: DECODE THE FUTURE OF AI AND CUSTOMER EXPERIENCE AT ELEVATE'25 DIGITAL INNOVATION SUMMIT With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. Taking place on October 15, 2025, at the i

Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct

Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release

Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we

Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release

AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by

illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release

illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye